ARHGEF12 and bladder transitional cell carcinoma: Additionally, our study reveals a novel molecular regulatory circuit driving cisplatin resistance in BLCA: ARHGEF12 activates the PI3K–Akt axis by modulating the RhoA/ROCK pathway, thereby promoting resistance in BLCA cells.